Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab oral corticosteroid-sparing study in severe corticosteroid-dependent asthma
NL-OMON42207Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Lebrikizumab with Placebo (2 arms). Started Sep 2015; status: active, not recruiting.
02
Drugs
lebrikizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON42207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42207.